Pharma BD Deal Intelligence
Camurus granted Eli Lilly exclusive worldwide rights to research, develop, manufacture and commercialize long-acting incretin products for cardiometabolic health built on Camurus' FluidCrystal injection depot technology, covering up to four Lilly proprietary compounds selected from dual GIP/GLP-1 receptor agonists and triple GIP/glucagon/GLP-1 receptor agonists, with an option to add amylin receptor agonists. Camurus is eligible for up to $290 million in upfront, development and regulatory milestones, up to $580 million in sales-based milestones, and tiered mid-single-digit royalties.